TITLE

FDA approves third pancrelipase product

AUTHOR(S)
Traynor, Kate
PUB. DATE
May 2010
SOURCE
American Journal of Health-System Pharmacy;5/15/2010, Vol. 67 Issue 10, p776
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that the U.S. Food and Drug Administration (FDA) has approved the pancreaze used for the treatment of exocrine pancreatic insufficiency caused by cystic fibrosis. It informs that pancreaze was introduced by the company Johnson & Johnson Pharmaceutical Research and Development LLC. FDA has also approved the labelling for pancreaze includes different dosages for different age groups.
ACCESSION #
50597339

 

Related Articles

  • FDA Accepts Basilea's Response.  // BioWorld Today;9/16/2008, Vol. 19 Issue 180, p5 

    The article reports that the U.S. Food and Drug Administration has accepted for review a complete response to a not approvable letter for the drug ceftobiprole of Basilea Pharmaceutic Ltd. The U.S. application for the drug as a treatment for complicated skin and skin structure infections have...

  • Basilea Falls as FDA Delays Ceftobiprole Decision Again. Hollingsworth, Catherine; Sheridan, Cormac // BioWorld International;12/3/2008, Vol. 13 Issue 49, p1 

    The article reports on the move of the U.S. Food and Drug Administration (FDA) to delay its review of cephalosporin antibiotic ceftobiprole due to unresolved "data integrity issues." This move has been an unexpected setback for Basilea Pharmaceutical Ltd. and co-development partner Johnson &...

  • Schizophrenia Update.  // PharmaWatch: CNS;Sep2006, Vol. 5 Issue 9, p15 

    The article reports developments related to schizophrenia in the U.S. AstraZeneca PLC seeks approval from the Food and Drug Administration (FDA) for a sustained release formulation of its drug Seroquel for the treatment of schizophrenia. A review of Johnson & Johnson Pharmaceutical Research &...

  • Basilea Falls as FDA Delays Ceftobiprole Decision Again. Hollingsworth, Catherine // BioWorld Today;12/1/2008, Vol. 19 Issue 232, p1 

    The article reports that shares of Swiss biotechnology firm Basilea Pharmaceutica Ltd. fell 36 percent on November 26, 2008 on news that the U.S. Food and Drug Administration (FDA) again delayed its review of cephalosporin antibiotic ceftobiprole due to unresolved data integrity issues. The drug...

  • FDA Slaps J&J's Sloppy Work Monitoring Ceftobiprole Trials. Young, Donna // BioWorld Today;8/20/2009, Vol. 20 Issue 160, p1 

    The article reports on the warning by the U.S. Food and Drug Administration (FDA) to Johnson & Johnson Pharmaceutical Research & Development about objectionable conditions observed by government inspectors at clinical trial sites testing the drug ceftobiprole. The drug is a broad-spectrum...

  • Regulatory Update.  // PharmaWatch: CNS;Dec2011, Vol. 10 Issue 12, p22 

    The article offers regulatory news briefs. Mylan Pharmaceuticals Inc. receives U.S. Food & Drug Administration (FDA) approval for the generic version of Purdue Pharma's MS Contin opioid analgesic. The FDA approved the Nucynta ER of Johnson & Johnson Pharmaceutical Research & Development L.L.C....

  • FDA Approves Addition of Sustained Overall Survival Advantage (5-year follow-up) to Label for VELCADE in Patients with Previously Untreated Multiple Myeloma.  // Biomedical Market Newsletter;11/7/2011, Vol. 21, p645 

    The article reports on the approval of the supplemental new drug application (sNDA) for VELCADE bortezomib for injection by the U.S. Food and Drug Administration (FDA). FDA has given permission to include additional overall survival (OS) data for VELCADE in patients with previously untreated...

  • Psychiatry.  // PharmaWatch: CNS;Feb2009, Vol. 8 Issue 2, p11 

    The article offers news briefs related to schizophrenia. The Alkermes Inc., together with its partner Johnson & Johnson Pharmaceutical Research and Development LLC, has declared the Phase I study of an injectable formulation for schizophrenia treatment. The Memory Pharmaceuticals Corp. had...

  • Data Monitoring Deficiencies Sink Ceftobiprole Once Again. Boggs, Jennifer // BioWorld International;1/6/2010, Vol. 15 Issue 1, p4 

    The article reports on the failure of the antibiotic ceftobiprole from Basilea Pharmaceutica AG to clear U.S. Food and Drug Administration (FDA) review due to data integrity issues. The failure has led to the 15 percent decline of Basilea's shares. Basilea has an ongoing legal action against...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics